Metrics Contract Services
Metrics Contract Services is a full service pharmaceutical development and manufacturing organization serving clients worldwide.
Who We Are
Metrics Contract Services is a full service pharmaceutical development and manufacturing organization serving clients worldwide. We deliver proven scientific and operational excellence for oral dosage forms. Today, as a subsidiary of Mayne Pharma Group, we offer clients more resources and capabilities than ever before.
Areas of Expertise
Pharmaceutical Development and Clinical Trial Materials Manufacturing
We offer comprehensive formulation development services from preclinical through Phase III CTM including: tableting, immediate release, modified release (including controlled/matrix and sustained release), capsule filling, milling, micronizing, enteric coating, spray drying, extrusion, and spheronization. Our facilities and processes are designed to handle potent products, cytotoxic compounds, and controlled substances.
Analytical Services
Metrics analyzes the physical and chemical characteristics of drug substances and drug products through development and validation of methods, release, and stability testing.
Potent Products
Our potent facilities provide total engineered containment through customized, hardwall isolation technologies. Containment is achieved at 30 nanograms per cubic meter of room air; equipment and change parts are dedicated exclusively to potent use. Our facility features independent entry, exit and equipment double airlocks, decontamination showers, dedicated washroom, dedicated equipment storage, and pass through for product/waste.
Fast Track First Time In Man (FTIM) Studies
Metrics has successfully delivered materials for over 150 FTIM studies. Our process ensures speed and quality, with a 16-24 week timeline from receipt of well-characterized NCE to shipment to the clinic. Services include stability studies, analytical methods development, and validation.
Concept to Commercialization
The parent company of Metrics Contract Services, Mayne Pharma, recently invested $80 million to significantly expand facilities and equipment at its site in Greenville, NC. The new 126,000-sq-ft, oral dose commercial manufacturing facility quadruples the company’s US manufacturing capacity. This means Metrics can offer a more complete “concept to commercialization” solution in one contiguous location for clients, providing larger scale and increased capabilities for seamless scale-up, eliminating the need for site transfers.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
The Role of Forced Degradation in Method Development, Manufacturability, and CMC Strategy
April 28th 2025Forced degradation studies are critical in biologics development, particularly for monoclonal antibodies (mAbs). These studies simulate long-term environmental stressors to uncover degradation pathways and ensure the stability of critical quality attributes (CQAs), aiding in robust chemistry, manufacturing, and controls (CMC) strategies and regulatory compliance.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
